858 — Extrawell Pharmaceutical Holdings Income Statement
0.000.00%
Last trade - 00:00- HK$209.10m
- -HK$644.56m
- HK$55.43m
- 46
- 93
- 44
- 69
Annual income statement for Extrawell Pharmaceutical Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 78.8 | 73.9 | 72.6 | 59.1 | 55.4 |
| Cost of Revenue | |||||
| Gross Profit | 42.6 | 37.6 | 31.1 | 28.8 | 21.9 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 184 | -75.3 | -77.8 | 198 | -194 |
| Operating Profit | -106 | 149 | 150 | -138 | 249 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -120 | 132 | 131 | -160 | 225 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -120 | 131 | 130 | -162 | 224 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -121 | 131 | 129 | -163 | 223 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -121 | 144 | 145 | -163 | 245 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.051 | 0.044 | 0.044 | -0.068 | 0.102 |